Moreover, platelet-coated cancer cells exhibit less detectable CD112 and CD155 on their cell surface, which act as ligands for the activating NK cell receptor DNAM-1 [281], which further reduces the immune response toward cancer cells. This evidence concerns the gene CD226 and cancer.